InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria
Rhea-AI Summary
InflaRx (Nasdaq: IFRX) expects to report topline Phase 2a clinical data for oral C5aR inhibitor INF904 in hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU) in a pre-market press release on November 10, 2025.
The company will host a webcast and slide presentation on November 10, 2025 at 8:00 AM EST / 2:00 PM CET and also expects to publish third quarter 2025 financial results via Form 6-K the same day pre-market.
Positive
- Topline data release scheduled for Nov 10, 2025
- Q3 2025 financial results to be published pre-market Nov 10, 2025
- Webcast presentation set for 8:00 AM EST / 2:00 PM CET
Negative
- None.
News Market Reaction 26 Alerts
On the day this news was published, IFRX gained 2.50%, reflecting a moderate positive market reaction. Argus tracked a peak move of +31.6% during that session. Our momentum scanner triggered 26 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $83M at that time. Trading volume was exceptionally heavy at 20.5x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
- Company expects to host a webcast to discuss the topline data on Monday, November 10 at 8:00 AM EST / 2:00 PM CET
- Company also expects to publish third quarter 2025 financial results on the same day pre-market
JENA, Germany, Nov. 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it expects to report topline data from the Phase 2a clinical trial of oral C5aR inhibitor INF904 in patients with hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU) in a pre-market press release on Monday, November 10, 2025.
InflaRx expects to host a webcast/conference call accompanied by a slide presentation on Monday, November 10, 2025, at 8:00 AM EST / 2:00 PM CET to discuss the topline clinical data, and to also feature key opinion leader insight. To participate in the call, participants may pre-register here to receive an invite link and dial-in details. The live webcast and audio archive of the presentation can be accessed on the InflaRx website at https://www.inflarx.de/Home/Investors/Events.html.
In addition, the Company expects to publish its third quarter 2025 financial and operating results via Form 6-K on the same day pre-market.
About InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx has developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies. InflaRx is also developing INF904, an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor.
InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).
Contacts:
| InflaRx N.V. | MC Services AG |
| Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de | Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752 |
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the heading “Risk factors” and “Cautionary statement regarding forward looking statements” in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
FAQ
When will InflaRx (IFRX) release topline Phase 2a data for INF904?
What time is the InflaRx (IFRX) webcast to discuss INF904 topline data?
Will InflaRx (IFRX) publish financial results with the INF904 readout?
How can investors access the InflaRx (IFRX) INF904 presentation webcast?
What indications are included in the INF904 Phase 2a topline readout by InflaRx (IFRX)?
